Cd33 antibodies and use of same to treat cancer
AssigneeSeattle Genetics, Inc.
InventorsMay Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
Life of this patent
Estimating the term…
Abstract
The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
Claims50
An isolated antibody that specifically binds to the human CD33 protein, wherein the antibody comprises three heavy chain complementarity determining regions (CDRs):
- heavy chain CDR1 consisting of SEQ ID NO:19, heavy chain CDR2 consisting of SEQ ID NO:20, and heavy chain CDR3 consisting of SEQ ID NO:21;
- and three light chain CDRs:
- light chain CDR1 consisting of SEQ ID NO:22, light chain CDR2 consisting of SEQ ID NO:23, and light chain CDR3 consisting of SEQ ID NO:24.
The antibody of any of the preceding claims, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
A method of treating a patient having or at risk of having a cancer that expresses CD33, comprising administering to the patient an effective regime of a humanized antibody of any of the preceding claims.
A humanized antibody comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to HI (SEQ ID NO:18) and a mature light chain variable region at least 90% identical to LG (SEQ ID NO:8).
A humanized antibody comprising a mature heavy chain variable region comprising the 3 CDRs of SEQ ID NO:18 and wherein positions H48, H66, H67, H69, H71 and H94 are occupied by I, K, A, L, A and S respectively, and a mature light chain variable region comprising the 3 CDRs of SEQ ID NO:8, and wherein positions L22, L46, L69 and L71 are occupied by N, T, Q and Y, respectively.
A pharmaceutical composition comprising a humanized antibody of any preceding claim.
Dependencies are inferred from the claim text.